Corpus Intelligence IC Memo — SCOTT AND WHITE MEMORIAL HOSPITAL 2026-04-26 09:55 UTC
IC Memo — SCOTT AND WHITE MEMORIAL HOSPITAL
Investment Committee Memorandum | TX | 616 beds | Grade B | EBITDA uplift $136.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

SCOTT AND WHITE MEMORIAL HOSPITAL

CCN 450054 | BELL, TX | 616 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

SCOTT AND WHITE MEMORIAL HOSPITAL is a 616-bed large academic medical center in BELL, TX with $1.85B in net patient revenue and a -10.5% operating margin. The hospital serves a payer mix of 18.0% Medicare, 1.8% Medicaid, and 80.2% commercial.

Thesis: Undervalued. Our ML models identify $136.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -10.5% to -3.1% (+736bps).

Net Revenue HCRIS$1.85B
Current EBITDA COMPUTED$-194.1M
Operating Margin COMPUTED-10.5%
Occupancy HCRIS83.3%
Revenue / Bed COMPUTED$3.0M
Net-to-Gross HCRIS24.5%
Distress Probability ML38.1%

2. Market Context & Competitive Position

583
TX Hospitals
-0.7%
State Median Margin
54
Comparable Hospitals

TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of -10.5% places it below the state median. Among 54 size-comparable peers (308-1232 beds), the median margin is 3.5%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (308-1232), prioritizing same-state peers. 54 hospitals in the comp set.

HospitalStateBedsRevenueMargin
SCOTT AND WHITE MEMORIAL HOSPI (Target)TX616$1.85B-10.5%
UT MD ANDERSON CANCER CENTERTX721$4.90B-0.8%
MEMORIAL HERMANN TEXAS MEDICALTX1089$2.64B2.8%
THE METHODIST HOSPITALTX966$2.63B5.2%
TEXAS CHILDRENS HOSPITALTX863$2.50B-29.9%
UT SOUTHWESTERN UNIVERSITY HOSTX737$2.28B-4.6%
CHILDRENS MEDICAL CENTER OF DATX377$1.56B10.3%
COOK CHILDRENS MEDICAL CENTERTX423$1.51B16.5%
MEDICAL CITY DALLASTX819$1.33B49.7%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $136.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$38.9M+210bp18mo
Cost to Collect4.5%2.5%$37.1M+200bp12mo
Denial Rate Reduction12.0%6.5%$36.7M+198bp12mo
A/R Days Reduction5200.0%3800.0%$22.6M+122bp9mo
Clean Claim Rate88.0%96.0%$1.2M+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$38.9M
Cost to Collect
$37.1M
Denial Rate Reduction
$36.7M
A/R Days Reduction
$22.6M
Clean Claim Rate
$1.2M
Total EBITDA Uplift$136.4M
Current EBITDA$-194.1M
+ RCM Uplift+$136.4M
Pro Forma EBITDA$-57.7M
Current Margin-10.5%
Pro Forma Margin-3.1%
WC Released (1x)$71.1M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-298.7M$83.7M0.00x-100.0%
Base (11x exit)10.0x11.0x$-298.7M$-4.9M0.00x-100.0%
Bull Case9.0x11.0x$-268.8M$348.3M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-268.8M$300.6M0.00x-100.0%
Bear Case11.0x10.0x$-328.5M$-501.4M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-328.5M$-658.3M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 54 hospitals with 308-1232 beds
  • Same-state prioritization (n=55)
  • Comp margins: P25=-15.1% / P50=3.5% / P75=12.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.